Navigation Links
AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
Date:2/21/2008

WILMINGTON, Del., Feb. 21 /PRNewswire-FirstCall/ -- AstraZeneca believes this lawsuit is legally and factually unfounded and we intend to appeal to the Alabama Supreme Court, if the trial court does not reject the jury's verdict. The case was based on the misleading premise that the Alabama State Medicaid Agency did not understand the basics on how drug prices are established and reported.

We believe numerous errors occurred during the proceedings and that the verdict should not be upheld.

For example, the Court ruled that important information on the workings of the Alabama pharmacy system be withheld throughout the trial. The Court also permitted evidence of earlier, unrelated settlements and proceedings in clear violation of the rules of evidence. These and other reversible errors were compounded by negative public comments by the trial lawyers and state leaders prior to the jury selection process.

AstraZeneca has fully complied with the law, government guidelines and contracts that govern Medicaid pricing. We currently provide medicines to Medicaid programs at the lowest price that we offer to our best business clients, as federal law requires.

AstraZeneca and the State Medicaid program share a common goal of helping people access the medicines they need.

To help patients who have difficulty affording their medicines, we offer patient assistance programs side by side with our medicines. In the last two years alone, AstraZeneca helped more than 28,800 Alabama patients receive more than $25.5 million in savings through its prescription savings programs.


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
2. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
3. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
4. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
5. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
6. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
7. Statement by John Bailey, Chief Scientist: The Personal Care Products Council Response to Study on Phthalate Exposure in Baby Care Products
8. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
9. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
10. Triage study challenges notions of emergency medical response to disaster
11. CNS Response, Inc. Announces Acquisition of Neuropsychiatric Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the leader ... recently announced the formation of the company,s Medical and ... the addition of Dr. William E. Gannon, Jr. ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with Dr. ... of therapeutic areas and set strategic goals for the ...
(Date:8/19/2014)... 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or ... results of its Oral Amphotericin B (Oral Amp ... study, conducted by ImmuneCarta®, the immune monitoring business ... effectiveness of Oral Amp B in reactivating latent ... despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... Tampa, FL (Aug. 18, 2014) -- A new ... South Florida (USF) Morsani College of Medicine and ... the life-threatening complications of interventional cardiovascular disease treatment. ... model that the novel molecular therapy could selectively ... healing following a medical procedure using a balloon ...
(Date:8/18/2014)... Aug. 18, 2014   Sterne, Kessler, Goldstein & ... Washington, DC , announced today that ... Review (IPR) with the U.S. Patent and Trademark ... of BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions ... by Myriad Genetics, Inc. These patents have been asserted ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... NOVATO, Calif., March 31 BioMarin,Pharmaceutical Inc. (Nasdaq ... (AnGes), BioMarin,s marketing and distribution partner in Japan, ... from the Japanese Ministry of Health, Labour and ... VI ( MPS,VI)., "We are proud to ...
... performance module implemented in just few months, organization kicks ... ... personal growth, OTTAWA, March ... employee performance and talent management software,today announced that Beaumont Hospitals ...
... March 31 Transave Inc.,reported today that its ... have the ability to penetrate mucus and,biofilms, and ... patients with cystic fibrosis, according to results of ... Results of the study titled "Biofilm penetration, ...
Cached Biology Technology:Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4Beaumont Hospitals in Michigan Selects Halogen Software for Pay for Performance System 2Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 2Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 3Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 4
(Date:8/20/2014)... of 158 pregnant teenagers in Rochester, NY, nearly half ... of ice, cornstarch, vacuum dust, baby powder and soap, ... , Moreover, such teens had significantly lower iron levels ... substances. , Pregnant teens, regardless of pica, are at ... iron deficiency and anemia. Low iron in pregnant teens ...
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... and can quickly become life threatening for some children.    ... as 1.2 million Canadians have food allergies and this number ... cent of children are estimated to have food allergies.  ... mild skin irritations and hives to breathing difficulties and loss ...
(Date:8/20/2014)... WORCESTER, MA Using population-based screening outcomes of approximately ... states, including four researchers at the University of Massachusetts ... combined immunodeficiency (SCID) can be successfully implemented across public ... programs published in the Aug. 20 issue of the ... JAMA ) showed the rate of SCID in newborns ...
Breaking Biology News(10 mins):Pica in pregnant teens linked to low iron 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... 2007 Today, researchers report for the first ... that are inherited only from the motherare directly linked ... study, which highlights the role of mitochondrial genome variation ... in Genome Research ( www.genome.org ). ...
... (NPL) is part of Biotesting Europe, a new 358,000 ... will ensure that future testing procedures and facilities meet ... in this growing industry. Biometric recognition systems measure ... can be as varied as iris images, fingerprints, the ...
... smoking can be harmful, if not deadly. While the desire ... factors also play an important role. The etiology of these ... the environment. Adoption and twin studies have shown that the ... studies have provided evidence that ones sex can influence the ...
Cached Biology News:Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes 2UK scientists working to help cut ID theft 2Does the desire to consume alcohol and tobacco come from our genetic makeup? 2Does the desire to consume alcohol and tobacco come from our genetic makeup? 3
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... Modules Highly efficient ... cloning into advanced λ ... For flexibility ... Systems, the modules of ...
... While antigen and antibody-based immunoaffinity ... been reused many times without compromising ... extremes and chaotropic agents has precluded ... Western blotting. The CHEMICON Re-Blot ...
Biology Products: